NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $363.55 +3.33 (+0.92%) (As of 04:18 PM ET) Add Compare Share Share Today's Range$359.29â–Ľ$364.4550-Day Range$311.04â–Ľ$360.2252-Week Range$208.62â–Ľ$365.98Volume436,011 shsAverage Volume494,663 shsMarket Capitalization$16.13 billionP/E Ratio17.19Dividend YieldN/APrice Target$350.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside3.6% Downside$350.36 Price TargetShort InterestBearish9.47% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment1.03Based on 30 Articles This WeekInsider TradingSelling Shares$37.73 M Sold Last QuarterProj. Earnings Growth12.39%From $24.86 to $27.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.20 out of 5 starsMedical Sector155th out of 940 stocksPharmaceutical Preparations Industry60th out of 435 stocks 2.3 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 9 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageUnited Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.47% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in United Therapeutics has recently increased by 0.49%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 2.8 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for United Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 7 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,729,687.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 12.39% in the coming year, from $24.86 to $27.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 17.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.58.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 17.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.89.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone ResearchAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesAugust 29 at 10:35 AM | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $93,722.29 in StockAugust 22, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of StockAugust 30, 2024 | Brownstone Research (Ad)AI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowAugust 9, 2024 | insidertrades.comMichael Benkowitz Sells 25,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockAugust 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesAugust 6, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek Sells 5,000 SharesAugust 30 at 3:30 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Sets New 12-Month High on Analyst UpgradeAugust 30 at 2:25 AM | americanbankingnews.comAnalysts Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $334.45August 30, 2024 | Brownstone Research (Ad)AI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowAugust 29 at 4:27 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Increased to $575.00 by Analysts at OppenheimerAugust 28 at 5:51 PM | seekingalpha.comLiquidia requests preliminary injunction against FDA for Tyvaso 3-year exclusivityAugust 28 at 5:51 PM | finance.yahoo.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?August 28 at 10:17 AM | americanbankingnews.comLeerink Partnrs Equities Analysts Boost Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)August 28 at 2:12 AM | americanbankingnews.comEquities Analysts Set Expectations for United Therapeutics Co.'s Q1 2025 Earnings (NASDAQ:UTHR)August 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for United Therapeutics on Strengthened Tyvaso Franchise PositionAugust 21, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Reaches New 1-Year High at $344.26August 21, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) PT Raised to $380.00 at Wells Fargo & CompanyAugust 19, 2024 | seekingalpha.comUnited Therapeutics: Economics Support Compounding AbilitySee More Headlines Company Calendar Last Earnings7/31/2024Today8/30/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$350.36 High Stock Price Target$575.00 Low Stock Price Target$240.00 Potential Upside/Downside-3.0%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$21.15 Trailing P/E Ratio17.08 Forward P/E Ratio14.53 P/E Growth1.25Net Income$984.80 million Net Margins40.87% Pretax Margin53.54% Return on Equity18.82% Return on Assets15.61% Debt Debt-to-Equity Ratio0.02 Current Ratio4.35 Quick Ratio4.18 Sales & Book Value Annual Sales$2.62 billion Price / Sales6.12 Cash Flow$23.03 per share Price / Cash Flow15.69 Book Value$128.05 per share Price / Book2.82Miscellaneous Outstanding Shares44,356,000Free Float38,812,000Market Cap$16.03 billion OptionableOptionable Beta0.55 Social Links Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonExecutive Vice President of Product Development & XenotransplantationMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVAReata PharmaceuticalsNASDAQ:RETABlueprint MedicinesNASDAQ:BPMCBridgeBio PharmaNASDAQ:BBIOPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsMartine A RothblattSold 269 sharesTotal: $93,722.29 ($348.41/share)Cetera Investment AdvisersBought 493 shares on 8/22/2024Ownership: 0.014%Truist Financial CorpSold 694 shares on 8/21/2024Ownership: 0.019%Brandes Investment Partners LPBought 926 shares on 8/19/2024Ownership: 0.045%B. Riley Wealth Advisors Inc.Bought 99 shares on 8/19/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $219.89 at the beginning of 2024. Since then, UTHR shares have increased by 65.3% and is now trading at $363.55. View the best growth stocks for 2024 here. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday, July, 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by $0.48. The company's quarterly revenue was up 19.8% compared to the same quarter last year. What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. Who are United Therapeutics' major shareholders? Top institutional investors of United Therapeutics include Renaissance Technologies LLC (4.89%), LSV Asset Management (2.18%), AQR Capital Management LLC (1.62%) and Dimensional Fund Advisors LP (1.32%). Insiders that own company stock include Paul A Mahon, Louis W Sullivan, Judy D Olian, Nilda Mesa, Christopher Causey, Michael Benkowitz, Raymond Dwek, Martine A Rothblatt and Christopher Patusky. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE) and Johnson & Johnson (JNJ). This page (NASDAQ:UTHR) was last updated on 8/30/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored2:59 PM Friday. Make this trade.By just placing one simple trade around 2:59 pm on Friday… You’re going to be SHOCKED.Timothy Sykes | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredBuffett’s Dirty Little Secret [EXPOSED!]I'm sure you've heard Warren Buffett publicly slam gold as an investment… But here's the twist…Buffett's ac...Colonial Metals | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding United Therapeutics Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.